Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 207

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 207
---
exercise price of $45,070.73 per share)                             |     |     |            7 |     |     |            7 |
| Rollover RSU awards outstanding                                                        |     |     |            3 |     |     |            3 |
| Stock options outstanding (minimum exercise price $571.20)                             |     |     |           64 |     |     |           64 |
| Shares reserved for issuance                                                           |     |     |      960,469 |     |     |        2,422 |
| Shares available for future stock grants under the 2021 Equity Incentive Plan          |     |     |       10,142 |     |     |        1,288 |
| Total common stock reserved for issuance                                               |     |     |      970,611 |     |     |        3,710 |

9. Stock-Based Compensation 2021 Equity Incentive Plan In January 2022, the Board of Directors and the Company’s stockholders adopted the 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan is administered by the Board of Directors. Vesting periods and other restrictions for grants under the 2021 Plan are determined at the discretion of the Board of Directors. Grants to employees, officers, directors, advisors, and consultants of the Company typically vest over oneto fouryears. In addition, the number of shares of stock available for issuance under the 2021 Plan will be automatically increased each January 1, and began on January 1, 2022, by 10% of the aggregate number of outstanding shares of our common stock from the first day of the preceding calendar yearto the first day of the current calendar year or such lesser number as determined by our board of directors. On May 15, 2024 at the Company’s 2024 Annual Meeting of Stockholders, an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the Plan to 10,206was approved. F-18 REVELATION BIOSCIENCES, INC.
Notes to the Consolidated Financial Statements 9. Stock-Based Compensation(cont.)

Under the 2021 Plan, stock
options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than %
of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding
10% or more